Wednesday, November 30, 2022
Sanofi's sleeping sickness drug cures 95% of people in phase 2/3 trial, boosting plan to stop transmission
Sanofi’s oral sleeping
sickness candidate acoziborole has achieved 95% efficacy in a late-phase
clinical trial, delivering a boost to a global push to interrupt transmission
of the parasitic disease by 2030.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment